Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

The Top 5 Biosimilar Articles for the Week of April 1

April 5th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of April 1, 2024.

Eye on Pharma: Biosimilar Ozempic; Celltrion Omalizumab Biosimilar Submission

April 4th 2024

By Skylar Jeremias

Article

A Chinese company has expressed interest in developing a biosimilar to Ozempic (semaglutide); Celltrion completed its biologic license application for its omalizumab biosimilar candidate.

Review Highlights Most Popular European Policies to Boost Biosimilar Uptake

April 3rd 2024

By Skylar Jeremias

Article

Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.

Quiz: Biosimilar Market Dynamics and Trends

April 2nd 2024

By The Center for Biosimilars Staff

Article

Have you been keeping up with the latest market trends? Take this quiz to find out how well you know the global biosimilars market.

BioRationality: President Biden’s 2025 Budget and Removing Biosimilar Interchangeability

April 1st 2024

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, outlines how President Joe Biden's new budget for 2025 could impact biosimilars, including provisions to clear up confusion surrounding interchangeable products.

Biosimilars Dermatology Roundup: March 2024

April 1st 2024

By Skylar Jeremias

Article

Between new data coming out of conferences, new insights into adalimumab biosimilars, and a study evaluating the impact of biosimilars on patient out-of-pocket costs, the biosimilar space had a very eventful March.

Biosimilars Dermatology Roundup for March 2024—Podcast Edition

March 31st 2024

By Skylar Jeremias

Podcast

On this episode of Not So Different, The Center for Biosimilars® discusses all the conference coverage, adalimumab data, and market insights to come out of the biosimilar dermatology space in March 2024.

The Totality of Evidence Supporting Adalimumab Biosimilar AVT02

March 30th 2024

By Deana Ferreri, PhD

Article

A review article described the totality of evidence supporting the approval of the adalimumab biosimilar AVT02 (Simlandi; Alvotech) for all approved indications of the reference product, Humira.

Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs

March 29th 2024

By Skylar Jeremias

Article

Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.

An Overview of Adalimumab Biosimilars

March 29th 2024

By Jamie T. Brogan, MSN, APRN, FNP-BC

Video

Clinicians and a pharmacist provide an overview of the emerging adalimumab biosimilars in the recent years.